home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 07/18/19

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019

WARREN, N.J. , July 18, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm ® technology to meet patients' unmet needs and solve ...
AQST - Aquestive Therapeutics Completes $70 Million Debt Refinancing

WARREN, N.J. , July 15, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive"), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm ® technology to meet patients' unmet ne...

AQST - Healthcare dominate premarket gainers

Immunic (NASDAQ: IMUX ) +17% . More news on: Immunic, Inc., Foresight Autonomous Holdings Ltd., Jaguar Health, Inc., Stocks on the move, Read more ...

AQST - Aquestive Therapeutics (AQST) Investor Presentation - Slideshow

The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this Read more ...

AQST - Aquestive Therapeutics Completes Enrollment in Libervant(TM) (diazepam buccal film) Crossover Study

WARREN, N.J. , June 4, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company, today announced it has completed enrollment in a single dose crossover pharmacokinetic (PK) trial for Libervant ™ (diazepam buccal film), which is in develo...

AQST - Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

WARREN, N.J. , May 13, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today announced that managemen...

AQST - Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2019 Results - Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Daniel Barber...
AQST - Aquestive Therapeutics misses by $0.08, beats on revenue

Aquestive Therapeutics (NASDAQ: AQST ): Q1 GAAP EPS of -$0.59 misses by $0.08 . More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

AQST - Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights

WARREN, N.J. , May 8, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today reported financial results for...

AQST - IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

SAINT LAURENT, Quebec, May 08, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc. (NASDAQ:AQST) (...
Previous 10 Next 10